Taiichi Kaku Selected Research

JBP 485

10/2015	JBP485 promotes corneal epithelial wound healing.
5/2015	JBP485 promotes tear and mucin secretion in ocular surface epithelia.
9/2013	JBP485 improves gentamicin-induced acute renal failure by regulating the expression and function of Oat1 and Oat3 in rats.
3/2013	OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485.
11/2012	Changes in expression of renal Oat1, Oat3 and Mrp2 in cisplatin-induced acute renal failure after treatment of JBP485 in rats.
7/2012	Effect of JBP485 on obstructive jaundice is related to regulation of renal Oat1, Oat3 and Mrp2 expression in ANIT-treated rats.
4/2011	Uptake, transport and regulation of JBP485 by PEPT1 in vitro and in vivo.
6/2009	Protective effect of JBP485 on concanavalin A-induced liver injury in mice.
7/2008	Protective effect of JBP485 on concanavalin A-induced hepatocyte toxicity in primary cultured rat hepatocytes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Taiichi Kaku Research Topics

Disease

4	Fibrosis (Cirrhosis) 01/2022 - 09/2017
4	Hepatitis 03/2013 - 07/2008
3	Alcoholic Fatty Liver 01/2020 - 09/2017
2	Iron Overload 01/2022 - 05/2019
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020 - 10/2019
2	Chronic Hepatitis (Chronic Active Hepatitis) 10/2019 - 05/2019
2	Inflammation (Inflammations) 05/2019 - 10/2015
2	Acute Kidney Injury (Acute Renal Failure) 09/2013 - 11/2012
1	Hemochromatosis (Bronze Diabetes) 01/2022
1	type 3 Hemochromatosis 01/2022
1	Renal Insufficiency (Renal Failure) 01/2022
1	Chronic Disease (Chronic Diseases) 10/2019
1	Cardiomegaly (Heart Hypertrophy) 10/2019
1	Cachexia 10/2019
1	Corneal Injuries 10/2015
1	Dry Eye Syndromes (Dry Eye Syndrome) 05/2015
1	Obstructive Jaundice (Cholestatic Jaundice) 07/2012
1	Necrosis 06/2009

Drug/Important Bio-Agent (IBA)

9	JBP 485IBA 10/2015 - 07/2008
3	Choline (Choline Chloride)IBA 01/2020 - 09/2017
3	Placental ExtractsIBA 01/2020 - 09/2017
2	IronIBA 01/2022 - 05/2019
2	DipeptidesIBA 03/2013 - 04/2011
1	HepcidinsIBA 01/2022
1	Transferrin Receptors (Transferrin Receptor)IBA 01/2022
1	Imipenem FDA Link 01/2022
1	Inosine Monophosphate (IMP)IBA 01/2022
1	Methionine (L-Methionine)FDA Link 01/2020
1	Angiotensin IIIBA 10/2019
1	Gentamicins (Gentamicin)FDA LinkGeneric 09/2013
1	entecavir FDA Link 03/2013
1	Cisplatin (Platino)FDA LinkGeneric 11/2012
1	Pharmaceutical PreparationsIBA 06/2009
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 06/2009
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2009

Therapy/Procedure

1	Therapeutics 01/2022
1	Aftercare (After-Treatment) 11/2012